Zhaoke Ophthalmology's (HKG:6622) presbyopia drug YUVEZZI has been approved by Macau's Pharmaceutical Administration Bureau for the treatment of age-related near vision loss, according to a Monday Hong Kong bourse filing.
The company said it plans to seek access for the drug under the Hong Kong-Macau Medicine and Equipment Connect program to support its early clinical use in the Greater Bay Area.